ブルトン型チロシンキナーゼ
出典: フリー百科事典『ウィキペディア（Wikipedia）』 (2022/09/05 08:47 UTC 版)
ブルトン型チロシンキナーゼ (Bruton's tyrosine kinase, 略称 Btk または BTK)は 酵素 のひとつで、ヒトでは BTK 遺伝子によりコードされている。 BTKは プロテインキナーゼ であり、リンパ球B細胞 の成熟に重要な役割を果たす。
- ^ a b c GRCh38: Ensembl release 89: ENSG00000010671 - Ensembl, May 2017
- ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000031264 - Ensembl, May 2017
- ^ Human PubMed Reference:
- ^ Mouse PubMed Reference:
- ^ “B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells”. European Journal of Haematology 94 (3): 193–205. (Mar 2015). doi:10.1111/ejh.12427. PMID 25080849.
- ^ X-Linked Agammaglobulinemia Patient and Family Handbook for The Primary Immune Diseases.
- ^ Astra Signals A Late Run On BTK Inhibition.
- ^ 臨床試験番号 NCT01659255 研究名 "ONO-4059 Phase I Dose-escalation Study to Investigate the Safety and Tolerability of ONO-4059 Given as Monotherapy in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma and/or Chronic Lymphocytic Leukaemi" - ClinicalTrials.gov
- ^ 臨床試験番号 NCT01351935 研究名 "Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia" - ClinicalTrials.gov
- ^ Novel BTK, PI3K Inhibitors on Horizon for Relapsed CLL.
- ^ BeiGene Announces Initiation of a Combination Trial of the BTK Inhibitor BGB-3111 with the PD-1 Antibody BGB-A317.
- ^ “Lilly inks a $690M deal to get its hands on an autoimmune drug” (英語). (2015年3月19日)
- ^ “The transcription factor, Bright, is not expressed in all human B lymphocyte subpopulations”. Cell. Immunol. 228 (1): 42–53. (March 2004). doi:10.1016/j.cellimm.2004.03.004. PMID 15203319.
- ^ a b “Cbl-b positively regulates Btk-mediated activation of phospholipase C-gamma2 in B cells”. J. Exp. Med. 196 (1): 51–63. (July 2002). doi:10.1084/jem.20020068. PMC 2194016. PMID 12093870.
- ^ “Identification of the SH2 domain binding protein of Bruton's tyrosine kinase as BLNK--functional significance of Btk-SH2 domain in B-cell antigen receptor-coupled calcium signaling”. Blood 94 (7): 2357–64. (October 1999). PMID 10498607.
- ^ “Functional interaction of caveolin-1 with Bruton's tyrosine kinase and Bmx”. J. Biol. Chem. 277 (11): 9351–7. (March 2002). doi:10.1074/jbc.M108537200. PMID 11751885.
- ^ “Identification of the binding site for Gqalpha on its effector Bruton's tyrosine kinase”. Proc. Natl. Acad. Sci. U.S.A. 95 (21): 12197–201. (October 1998). doi:10.1073/pnas.95.21.12197. PMC 22808. PMID 9770463.
- ^ “Mechanism of Bruton's tyrosine kinase-mediated recruitment and regulation of TFII-I”. J. Biol. Chem. 279 (8): 7147–58. (February 2004). doi:10.1074/jbc.M303724200. PMID 14623887.
- ^ “Regulation of nuclear localization and transcriptional activity of TFII-I by Bruton's tyrosine kinase”. Mol. Cell. Biol. 19 (7): 5014–24. (July 1999). doi:10.1128/mcb.19.7.5014. PMC 84330. PMID 10373551.
- ^ “BAP-135, a target for Bruton's tyrosine kinase in response to B cell receptor engagement”. Proc. Natl. Acad. Sci. U.S.A. 94 (2): 604–9. (January 1997). doi:10.1073/pnas.94.2.604. PMC 19560. PMID 9012831.
- ^ “Engagement of the human pre-B cell receptor generates a lipid raft-dependent calcium signaling complex”. Immunity 13 (2): 243–53. (August 2000). doi:10.1016/s1074-7613(00)00024-8. PMID 10981967.
- ^ “Bruton's tyrosine kinase (Btk) associates with protein kinase C mu”. FEBS Lett. 461 (1-2): 68–72. (November 1999). doi:10.1016/S0014-5793(99)01424-6. PMID 10561498.
- ^ “Identification and characterization of a novel SH3-domain binding protein, Sab, which preferentially associates with Bruton's tyrosine kinase (BtK)”. Biochem. Biophys. Res. Commun. 245 (2): 337–43. (April 1998). doi:10.1006/bbrc.1998.8420. PMID 9571151.
- ^ “Bruton's tyrosine kinase activity is negatively regulated by Sab, the Btk-SH3 domain-binding protein”. Proc. Natl. Acad. Sci. U.S.A. 96 (11): 6341–6. (May 1999). doi:10.1073/pnas.96.11.6341. PMC 26883. PMID 10339589.
[続きの解説]
「ブルトン型チロシンキナーゼ」の続きの解説一覧
- 1 ブルトン型チロシンキナーゼとは
- 2 ブルトン型チロシンキナーゼの概要
- 3 機能
- 4 相互作用
- ブルトン型チロシンキナーゼのページへのリンク
